Revolutionising organ specific RNA immunotherapies
Developing bioinspired lipid-like polymer technology to safely and specifically deliver nucleic acid therapeutics to immune cells in the body.
Our approach to addressing the limitations of current immuno-oncology treatments
Precision Delivery Systems
We engineer proprietary lipid-like polymer formulations that form non-immunogenic nanocarriers with tunable sizes able to effectively target extra-hepatic organs.
Genetic Payloads
We are developing siRNA and mRNA-based therapeutics that offer transformative alternatives to conventional antibody checkpoint inhibitors and CAR T cell therapies. Our approach addresses the key limitations of non-response with antibody checkpoint inhibitors, and poor manufacturability of ex-vivo CART cell therapies.
Focused Drug Development
Our lead programs are advancing a pipeline of mRNA and siRNA-based immunotherapies for oncology. We focus on mechanisms that reprogram immune responses at the genetic level—unlocking new treatment potential for patients who are underserved by current standards of care.
Our Technology
At Liporyx, we're developing next-generation formulations that revolutionize how RNA therapeutics are delivered to target tissues.
Lipid-Based Drug Delivery
Our proprietary innovations enable precise targeting of RNA therapeutics.
Most RNA therapeutics do not traverse the body well and are typically removed from circulation by the liver, limiting their effectiveness for many diseases. Liporyx has developed a bioinspired lipid-like polymer technology that overcomes these limitations.
Our technology creates non-immunogenic nanocarriers with tunable sizes that can effectively deliver therapeutic payloads directly into the cytosol of targeted cells. This precision delivery system is designed to maximize therapeutic efficacy while minimizing off-target effects.
The modular approach we've engineered enables us to unlock a vast array of therapeutic targets which are currently undruggable using existing formulations.
T Cells & Immunotherapies
Leveraging the immune system's power with RNA-based approaches.
Current immunotherapies face significant challenges: antibody checkpoint inhibitors often fail to elicit responses in many patients, while CAR-T cell therapies require complex ex-vivo manufacturing processes.
Liporyx is developing siRNA and mRNA-based therapeutics that offer transformative alternatives to these conventional approaches. Our technology enables:
- Direct genetic reprogramming of immune cells in vivo
- Enhanced targeting of immunosuppressive factors in the tumor microenvironment
- Simplified manufacturing compared to cell-based therapies
- Reduced immunogenicity and improved safety profiles
Our Team
Meet our dedicated team of scientists and industry professionals. The Liporyx team brings together deep expertise in formulation chemistry, drug development, and venture building.
Our Partners and Investors
We collaborate with leading institutions and have secured initial financing from a group of early-stage investors and funders including Biotech Booster, TU/e, and the NWO.
Latest News
Stay up to date with our latest developments and announcements.
Liporyx Attends EU-Funded NATPRIME Kick-Off Event
Liporyx is proud to share that we participated in the official kick-off event of NATPRIME, a newly launched EU-funded doctoral network focused on the next generation of RNA therapeutics. The event marked the start...
Liporyx Secures €200k Biotech Booster Grant to Advance RNA Therapeutics Platform
We're excited to announce that Liporyx has been awarded a Level 1 grant from the Biotech Booster program, part of the Dutch National Growth Fund initiative. This milestone grant provides crucial support as we take the next steps...
Novel Lipid-Like Polymer Hybrids for RNA Delivery
Our research team has developed a novel lipid-polymer hybrid system that significantly improves RNA delivery efficiency. The PCT patent application for our novel lipid-polymer hybrid system designed to significantly enhance...
Join our mission
Interested in collaborating, investing, or learning more about Liporyx? We'd love to hear from you.
Connect With Us
Follow us on social media for the latest updates, research highlights, and industry insights.
Helix building
Eindhoven University of Technology
5612AZ Eindhoven
The Netherlands